Xeris Biopharma Holdings (Nasdaq: XERS) announced the appointment of Menassie M. Taddese to its Board of Directors, effective November 2, 2026. Taddese, a former Viatris Emerging Markets President and 20-year Pfizer veteran, will also serve on the Board's Audit Committee. The appointment adds governance and financial expertise as Xeris advances its commercial portfolio and late-stage pipeline candidate XP-8121.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
